San Antonio Breast Cancer Review 2011
PURPOSE
This program, based on data presented at the San Antonio Breast Cancer Symposium 2011, is designed to provide state of the art information on experimental biology, etiology, prevention, diagnosis & therapy of breast cancer/premalignant breast disease to an audience of academic and private physicians and researchers involved in medical, surgical, GYN and radiation therapy, as well as other appropriate health care professionals.
OBJECTIVES
At the conclusion of this learning activity the participants should be able to:
• Identify new therapies available in breast cancer
• Determine length of hormonal treatments in the adjuvant setting
• Determine which patients with DCIS need radiation
• Identify patients who will benefit from the new treatments in advanced/metastatic disease
• Determine the role for adjuvant therapy
• Determine the importance of genomics.
• Determine whether all patients need axillary dissection
• Identify who needs adjuvant, hormonal or targeted therapy
• Identify new combination therapy for metastatic disease
CREDIT
Hackensack University Medical Center is Accredited by the Medical Society of New Jersey to provide Continuing Medical Education for physicians. Hackensack University Medical Center designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
REGISTRATION
To RSVP please contact Bonnie LoGiudice at 201-996-4891 or blogiudice@humed.com
AGENDA
| 7:00 – 7:30 AM | Registration with Continental Breakfast |
| 7:30 – 7:45 AM |
Welcome |
| 7:50 – 8:35 AM |
Risk Factor Profiles of Women with DCIS and Invasive Ductal Breast Cancer Freya R. Schnabel, MD Professor of Surgery, NYU School of Medicine |
| 8:40 – 9:25 AM |
New Systemic Chemotherapy in Metastatic Breast Cancer Mary Elizabeth Cianfrocca, DO Director, Breast Cancer Program Banner M.D. Anderson Cancer Center |
| 9:30 – 10:15 AM |
New Standard of Care for Radiation Therapy in Breast Cancer Lawrence J. Solin, MD, FACR Chairman, Radiation Oncology - Albert Einstein Medical Center |
| 10:15-10:30 AM | Break |
| 10:30 – 11:15 AM |
Molecular Profiling in Locally Advanced Breast Cancer Howard A. Burris, MD Chief Medical Officer, Sarah Cannon Research Institute |
| 11:20 – 12:05 PM |
Does Every Patient with Invasive Breast Cancer Require Adjuvant Therapy Edith A. Perez, MD Director of Breast Cancer Program, Mayo Clinic |
| 12:10-1:00 PM | Lunch |
| 1:00 – 1:45 PM |
Use of Rank Ligand Inhibitors in Breast Cancer Adam Brufsky, MD, PhD Professor of Medicine, University of Pittsburgh |
| 1:50 – 2:35 PM |
Efficacy and Adverse Events with Targeted Therapies Brian Leyland-Jones, MD Professor of Medicine, Emory University |
| 2:40 – 3:25 PM |
New Estrogen Receptor Blocker in Breast Cancer Harold A. Harvey, MD Milton S. Hershey Medical Center |